05 January 2024
05 January 2024
The FDA removes a partial clinical hold for Innate’s lacutamab trials following an investigation of a patient’s death.
In a move to drive down customer costs, AbbVie’s blockbuster therapy will be replaced by cheaper biosimilars.
The agreements could yield up to $1.44bn for Umoja in option exercise, development and regulatory milestone payments.
Roche will make milestone payments on meeting discovery, development and commercialisation goals totalling more than $2bn.
Agios plans to file regulatory approval for mitapivat by the end of the year after it met primary and secondary endpoints in the Phase III trial.
DSE will pay $100m to Esperion in mid-January 2024 on receipt of EMA approval for Nilemdo and Nustendi tablets.
The newly secured funds will be used to expedite the screening of new molecules and facilitate clinical studies.
The company secured FDA approval, paving the way for a Phase II clinical study of Vonafexor in Alport syndrome.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest thematic report will help you to understand and identify the important themes that threaten to disrupt your business in 2024. Our 2024 theme map covers not only disruptive tech themes but also ESG, macroeconomic, and regulatory themes. Reading this report is the first step towards making better business decisions in 2024.
Give your business an edge with our leading industry insights.
